Inovio Pharmaceuticals, Inc. is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of their medical products and clinical research.
In the following press release, Dr. J. Joseph Kim, Inovio’s President and CEO said that “These new data for H3N2 and Type B in animal models further validate our strategy to develop a universal vaccine to prevent known and unknown influenza strains, as well as our entire SynCon platform. We have in animals provided protection against all of the circulating influenza strains of the last 10 years.” Read the following article
Inovio Pharmaceuticals, Inc. is a biopharmaceutical company. It develops active DNA immunotherapies for cancer and infectious diseases. The company’s portfolio of immune therapies includes SynCon immunotherapies and electroporation delivery systems. Its pipeline consists vgx-3100, ino-3122, ino-3106, pennvax-b and pennvax-g. The company was founded on June 29, 1983 and is headquartered in Plymouth Meeting, PA. [Source: MarketWatch]
Company Website: http://www.inovio.com